Nature Cancer

Article	Citations
Outcompeting neighbors for intestinal cancer initiation	630
Gut decisions in CAR T cell therapy	420
Untangling the threads of immunotherapy research	410
Alzheimer’s drug turns macrophages against cancer	410
Enhancing childhood cancer targetability	351
Shooting for multiplexed pathology with Orion	337
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	321
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	316
Breaking frontiers with multidisciplinary cancer research	283
An oncolytic circular RNA therapy	258
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	247
PARP11 interfer(on)es with CAR T cell efficacy	228
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	215
A low-coverage liquid biopsy for lung cancer	212
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	211
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	204
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	204
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	196
A macrophage-activated abscopal effect	161
Considering molecular alterations as pan-cancer tissue-agnostic targets	158
MALAT1 protects dormant tumor cells from immune elimination	156
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	139
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	138
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	137
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	135

Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	133
The cGAS–STING pathway and cancer	132
DePICting T cell–APC crosstalk in cancer	132
Beating cancer one carbon at a time	121
Expanding the options for KRAS inhibition	119
Palmitate oxidation drives a pro-metastatic post-translational modification	116
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	112
Stress granules shape metabolic reprogramming and drug resistance	111
The importance of being generous	110
Bone marrow progenitor-like cells against leukemia cure	109
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	108
Shaping the microenvironment in peritoneal metastases	107
Reflecting on the golden age of cancer research	105
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	105
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	105
Impact of context-dependent autophagy states on tumor progression	99
Advancing therapeutics in small-cell lung cancer	97
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	95
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	94
Determinants of resistance and response to melanoma therapy	93
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	93
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	90
Innate immunity drives epithelial cell plasticity during prostate tumor formation	89
Sarcoma ecotypes determine immunotherapy benefit	89
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	89
A comeback for checkpoint inhibition in multiple myeloma	89
Antibody avidity meets multiple myeloma	88
Thriving in diverse ecosystems	87
Inflammation meets translation in AML	87
Evolving landscape of nasopharyngeal carcinoma therapy	87
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	86
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	86
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	85
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	85
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	85
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	84
Cycling back to folate metabolism in cancer	83
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	83
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	83
LAG-3 and PD-1 blockade raises the bar for melanoma	82
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	81
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	80
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	79
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	79
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	76
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	76
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	74
Radioligand cancer therapy comes to the fore	73
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	73
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	73

CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	70
Radiation sparks a dark side in neutrophils	70
Multimodal data integration improves immunotherapy response prediction	69
Dual inhibition of EGFR and PI3K with a single drug	67
Bispecific antibodies seek out colon cancer stem cells	67
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	66
How AI agents will change cancer research and oncology	66
Building a translational cancer dependency map for The Cancer Genome Atlas	65
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages	65
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	64
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	63
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	63
Immunotargeting of a recurrent AML-specific neoantigen	63
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	62
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	62
Targeting BRCA-mutated tumors in mitosis	61
Selective targeting of malignant T cells	61
AKTing on XPO1 inhibition in AML	61
GEMys homing in on metastasis	61
Highlights from the 2025 ASCO Annual Meeting	60
Bispecific chimeric T cell receptors tackle tumor heterogeneity	59
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets	59
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors	59
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	59
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export	59
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	58
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	58
Advances in antibody-based therapy in oncology	57
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer	57
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	57
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming	56
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models	56
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition	55
The tumor microenvironment’s role in the response to immune checkpoint blockade	55
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues	55
An antisense RNA promotes breast cancer metastasis via upregulation of NQO1	54
Anything to declare?	54
Neoadjuvant immunotherapy marks a new era in oncology	54
Epigenetic plasticity in PDAC	54
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	54
Myeloma evades T cell-engaging therapies	53
Metabolic symbiosis in pancreatic cancer	53
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	52
Estrogen receptor-positive breast cancer subtypes show differential macrophage functions	51
An unexpected career in cancer metabolism	51
In vivo macrophage engineering for renal cancer therapy	51
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	50
Author Correction: Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	50
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy	50
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation	50
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy	49
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	49
There are gremlins in prostate cancer	48
Targeting ADAR1 with a small molecule for the treatment of prostate cancer	48
Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	48
Ricolinostat is not a highly selective HDAC6 inhibitor	48
p53 at the crossroads of tumor immunity	48
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	47
Clinical and translational attributes of immune-related adverse events	47
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia	47
Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	46
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	46
Circumventing the roadblocks to targeting EGFR-driven cancers	46
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer	46
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	46
Masking T cell engagers mitigates on-target off-tumor activity	45
A new sophistication for breast cancer PDXs	45
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	45
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	44
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples	44
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	44
CAR T cell therapy: looking back and looking forward	44
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	44
Understanding the biology of lung cancer brain metastases	44
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors	43
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	43
Breaking the performance ceiling for neoantigen immunogenicity prediction	43
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	43
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	42
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	42

Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	41
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	41
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	41
CD8+ T cell killing of MHC class I–deficient tumors	41
Communicating with respect	40
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	40
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	40
CD4+ CAR T cells — more than helpers	39
Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis	39
The meaning of impact	39
Radiopharma pipeline builds ahead of key data	39
Insight from the ESMO Targeted Anticancer Therapies Congress 2025	37
Near-infrared optogenetic engineering of bacteria for cancer therapy	37
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	36
Acute lymphoblastic leukemia displays a distinct highly methylated genome	36
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors	36
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	36
Leveraging the potential for deintensification in cancer care	35
Artificial intelligence for prostate cancer diagnostics	35
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens	35
Harnessing the microbiome to restore immunotherapy response	34
Leveraging translational insights toward precision medicine approaches for brain metastases	33
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer	33
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	33
Disparities, aging and childhood cancer	32
Commensal metabolite boosts chemotherapy	32
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy	32
The aging lung reawakens dormant tumor cells	31
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer	31
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types	31
Fibrotic tumors tune metabolism for immune evasion	31
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	31
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	31
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy	31
The landscape of T cell antigens for cancer immunotherapy	31
Targeting HIF-1 to treat AML	30
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	30
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells	30
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer	30
Probing clonal dynamics with single-cell genomics	29
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells	29
The growing threat of cyberwarfare in cancer healthcare	29
Remodeling cyclophilin A to target KRAS	28
Checkpoint blockade regulates T cell fate by supporting co-stimulation	28
Bicarbonate transport as a vulnerability in pancreatic cancer	28
CAR T cell therapy for multiple myeloma	28
Not a generative AI–generated Editorial	28
Stargazing through the lens of AI in clinical oncology	28
Publisher Correction: Cancer’s new normal	28